VRC 607: A Phase 1, Single Dose Study of the Safety and Virologic Effect of a Human MonoclonalAntibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity,Administered Intravenously to HIV-Infected Adults.

Trial Profile

VRC 607: A Phase 1, Single Dose Study of the Safety and Virologic Effect of a Human MonoclonalAntibody, VRC-HIVMAB080-00-AB (VRC01LS), With Broad HIV-1 Neutralizing Activity,Administered Intravenously to HIV-Infected Adults.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs VRC 01LS (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions
  • Acronyms VRC 607
  • Most Recent Events

    • 22 Jun 2017 Planned End Date changed from 31 Aug 2018 to 1 May 2019.
    • 22 Jun 2017 Planned primary completion date changed from 31 Mar 2018 to 1 May 2018.
    • 07 Apr 2017 Planned primary completion date changed from 31 Mar 2017 to 31 Mar 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top